Zai Lab
Zai Lab Limited, a prominent biopharmaceutical company, is headquartered in Shanghai, China, with significant operations in the United States and Hong Kong. Founded in 2014, Zai Lab focuses on the discovery, development, and commercialisation of innovative therapies in oncology, autoimmune diseases, and infectious diseases. The company has achieved notable milestones, including strategic partnerships and the successful launch of several core products that address unmet medical needs. Zai Lab's unique approach combines cutting-edge science with a commitment to patient-centric solutions, positioning it as a leader in the biopharmaceutical industry. With a robust pipeline and a dedication to advancing healthcare, Zai Lab continues to make significant strides in improving patient outcomes globally.
DitchCarbon Score
How does Zai Lab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Development industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Zai Lab's score of 37 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Zai Lab's reported carbon emissions
In 2023, Zai Lab reported total greenhouse gas emissions of approximately 70,321,000 tonnes CO2e, comprising 65,642,000 tonnes CO2e from Scope 1 emissions, 4,664,000 tonnes CO2e from Scope 2 emissions, and 15,000 tonnes CO2e from Scope 3 emissions. This marked a significant increase in emissions compared to 2022, where total emissions were about 73,481,000 tonnes CO2e, with Scope 1 emissions at 70,463,000 tonnes CO2e and Scope 2 emissions at 3,954,000 tonnes CO2e. Zai Lab's emissions strategy includes a commitment to reducing its carbon footprint, although specific reduction targets have not been publicly detailed. The company has been assessed by the Carbon Disclosure Project (CDP), receiving a score of "C" in 2023, indicating a moderate level of transparency and action on climate-related issues. Zai Lab is also committed to near-term emissions reduction, although it has not set a net-zero target as of now. The pharmaceutical and biotechnology sector, in which Zai Lab operates, is under increasing scrutiny for its environmental impact, making the company's climate commitments particularly relevant in the context of global sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 28,400 | 00,000,000 | 00,000,000 |
| Scope 2 | 3,536,600 | 0,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Zai Lab is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
